{'fraction_non_alphanumeric': 0.025234318673395817, 'fraction_numerical': 0.002883922134102379, 'mean_word_length': 5.803921568627451, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An evaluation of mogamulizumab for the treatment of peripheral T-cell lymphoma

Introduction: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that remains extremely difficult to cure and has a poor prognosis with conventional chemotherapy; therefore, novel treatment modalities are needed. CC chemokine receptor 4 (CCR4) is expressed on the tumor cells of PTCL including adult T-cell leukemia-lymphoma (ATL) and is considered to be a promising therapeutic target. Mogamulizumab, a defucosylated, humanized anti-CCR4 mAb, is produced using a novel glycoengineering technology that enhances antibody-dependent cell-mediated cytotoxic activity. Areas covered: The basic aspects and current treatment strategies against PTCL including ATL were briefly reviewed, followed by a discussion on the development of mogamulizumab and clinical trials of this targeting agent for PTCL including ATL. Expert opinion: Mogamulizumab is the first therapeutic agent to target CCR4. Mogamulizumab monotherapy achieved a high response rate in patients with relapsed or refractory ATL and PTCL, with an acceptable toxicity profile. Furthermore, dose-intensified combination chemotherapy with mogamulizumab may be a promising treatment option for untreated patients with aggressive ATL, and may, therefore, provide effective and novel treatment strategies for PTCL and ATL.